



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	ATTACH 96 8/13/02
	FILING DATE January 23, 2002	GROUP 1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
LOO	AL1	EP 0 531 300 B1	03/17/1993	Europe	—	—	Yes No
LOO	AM1	EP 0 538 754 A2	04/28/1993	Europe	↓	↓	Yes No
LOO	AN1	WO 94/02633 A1	02/03/1994	WIPO	↓	↓	Yes No
LOO	AO1	WO 94/12631 A1	06/09/1994	WIPO	↓	↓	Yes No
LOO	AP1	WO 95/00851 A1	01/05/1995	WIPO	—	—	Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

LOO	AF	1	Breitz, H.B., et al., "Clinical Experience with Rhenium-186-Labeled Monoclonal Antibodies for Radioimmunotherapy: Results of Phase I Trials," J. Nucl. Med. 33:1099-1109, The Society of Nuclear Medicine (1992)
LOO	AS	1	Breitz, H.B., et al., "Pharmacokinetics and Normal Organ Dosimetry Following Intraperitoneal Rhenium-186-Labeled Monoclonal Antibody," J. Nucl. Med. 36:754-761, The Society of Nuclear Medicine (May 1995)
LOO	AT	1	Chatterjee, M.B. et al., "Idiotypic antibody immunotherapy of cancer," Cancer Immunol. Immunother. 38:75-82, Springer-Verlag (1994)

EXAMINER 	DATE CONSIDERED 2/2/04
--------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/952,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AL						
	AM						
	AN						
	AO						
	AP						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
LD	AI2	WO 95/00658 A1	01/05/1995	WIPO			Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

LD	AE	2	Chaudhary V.K. et al., "A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. USA</i> 87:1066-1070, National Academy Press (1990)
LD	AS	2	Ermak, G., et al., "Restricted Patterns of CD44 Variant Exon Expression in Human Papillary Thyroid Carcinoma," <i>Cancer Res.</i> 56:1037-1042, American Association for Cancer Research (March 1996)
LD	AT	2	Fox, S.B., et al., "CD44 and cancer screening," <i>Lancet</i> 342:546-549, Williams & Wilkins (1993)

EXAMINER 	DATE CONSIDERED 2/2/04
--------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0652.1510001/EYS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIJER et al.	
	FILING DATE January 23, 2002	GROUP 1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


RECEIVED  
AUG 13 2002  
TECH CENTER 1600/2300

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

HA	AF	3	Fox, S.B., et al., "Normal Human Tissues, in Addition to Some Tumors, Express Multiple Different CD44 Isoforms," Cancer Res. 54:4539-4546, American Association for Cancer Research (1994)
NO	AS	3	Friedrichs, K., et al., "CD44 Isoforms Correlate with Cellular Differentiation but not with Prognosis in Human Breast Cancer," Cancer Res. 55:5424-5435, American Association for Cancer Research (November 1995)
ho	AT	3	Fujiwara, K., et al., "Expression of a Lymphocyte Adhesion Molecule (CD44) in Malignant Lymphomas: Relevance to Primary Site, Histological Subtype and Clinical Stage," Acta Med. Okayama 47:215-222, Okayama University Medical School (1993)

EXAMINER 	DATE CONSIDERED 2/2/04
---	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER *et al.*FILING DATE  
January 23, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS




EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

RECEIVED  
AUG 15 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL					Yes No
	AM					Yes No
	AN					Yes No
	AO					Yes No
	AP					Yes No
	AQ					Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AF	4	Shaffari, S., et al., "Differentiation-Associated Changes in CD44 Isoform Expression During Normal Hematopoiesis and Their Alteration in Chronic Myeloid Leukemia," <i>Blood</i> 86:2976-2985, W.B. Saunders Company (October 1995)
	AG	4	Ginthert, U., et al., "A New Variant of Glycoprotein CD44 Confers Metastatic Potential to Rat Carcinoma Cells. <i>Cell</i> 65:13-24, Cell Press (1991)
	AT	4	Gura, T., "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> 278:1041-1042, American Association for the Advancement of Science (November 1997)

EXAMINER

DATE CONSIDERED

2/2/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 23, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AK	5	Heider, K.-H., et al., "A Human Homologue of the Fat Metastasis-associated Variant of CD44 Is Expressed in Colorectal Carcinomas and Adenomatous Polyps," J. Cell Biol. 120:227-233, The Rockefeller University Press (1993)
AS	5	Heider, K.-H., et al., "Expression of CD44 isoforms in human renal cell carcinomas," Virchows Arch. 428:267-273, Springer-Verlag (July 1996)
AT	5	Hofmann, M., et al., "CD44 Splice Variants Confer Metastatic Behavior in Rats: Homologous Sequences Are Expressed in Human Tumor Cell Lines." Cancer Res. 51:5292-5297, American Association for Cancer Research (1991)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTC-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0652.19100C1/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 23, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR	<u>6</u>	Horst, E., et al., "Expression of a Human Homing Receptor (CD44) in Lymphoid Malignancies and Related Stages of Lymphoid Development," <i>Leukemia</i> 4:383-393, Williams & Wilkins (1990)
	AS	<u>6</u>	Horst, E., et al., "Adhesion Molecules in the Prognosis of Diffuse Large-Cell Lymphoma: Expression of a Lymphocyte Homing Receptor (CD44), LFA-1 (CD11a, 19), and ICAM-1 (CD54)," <i>Leukemia</i> 4:595-599, Williams & Wilkins (1990)
	AT	<u>6</u>	Jackson, D.G., et al., "Multiple Variants of the Human Lymphocyte Homing Receptor CD44 Generated by Insertions at a Single Site in the Extracellular Domain," <i>J. Biol. Chem.</i> 267:4732-4739, The American Society for Biochemistry and Molecular Biology, Inc. (1992)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 23, 2002GROUP  
1542

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AD	AR	2	Jain, R.K., "Barriers to Drug Delivery in Solid Tumors," Sci. Am. 271:58-65, Scientific American, Inc. (1994)
BA	AS	2	Jalkanen, S., et al., "Lymphocyte Homing and Clinical Behavior of Non-Hodgkin's Lymphoma," J. Clin. Invest. 87:1835-1840, The American Society for Clinical Investigation, Inc. (1991)
W	AT	2	Juweid, M., et al., "Treatment of Non-Hodgkin's Lymphoma with Radiolabeled Murine, Chimeric, or Humanized LL2, an Anti-CD22 Monoclonal Antibody," Cancer Res. (Suppl.), 55:5899s-5907s, American Association for Cancer Research (December 1995)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 24, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

60	AF	E	Kaufmann, M., et al., "CD44 variant exon epitopes in primary breast cancer: and length of survival," <i>Lancet</i> 345:615-619, The Lancet, Ltd. (March 1995)
61	AG	E	Koopman, G., et al., "Activated Human Lymphocytes and Aggressive Non-Hodgkin's Lymphomas Express a Homologue of the Rat Metastasis-associated Variant of CD44," <i>J. Exp. Med.</i> 177:897-904, The Rockefeller University Press (1993)
62	AT	E	Mackay, C.R. et al., "Expression and Modulation of CD44 Variant Isoforms in Humans," <i>J. Cell. Biol.</i> 124:71-82, The Rockefeller University Press (1994)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 13/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1542

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AF	2	Müller, P., et al., "Venular endothelium binding molecules CD44 and LECA1-1 in normal and malignant B-cell populations. A comparative study," <i>Virchows Arch. A. Pathol. Anat.</i> 421:305-313, Springer-Verlag (1992)
	AE	15	Mulder, J.-W.R., et al., "Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins," <i>Lancet</i> 341:1470-1472, The Lancet, Ltd. (1994)
	AT	9	Pals, S.T., et al., "Expression of Lymphocyte Homing Receptor as a Mechanism of Dissemination in Non-Hodgkin's Lymphoma," <i>Blood</i> 73:885-888, Grune & Stratton (1989)

EXAMINER

DATE CONSIDERED

7/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 23, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>hfa</i>	AF	10	Pickar, L.J., et al., "Expression of Lymphocyte Homing Receptor Antigen in Non-Hodgkin's Lymphoma," Am. J. Pathol. 130:496-504, American Association of Pathologists (1988)
<i>lgl</i>	AE	10	Press, O. W., et al., "Phase II trial of I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas," Lancet 346:336-340, The Lancet, Ltd. (August 1995)
<i>W</i>	AT	10	Quadri, S.M., et al., "Evaluation of Indium-111- and Yttrium-90-labeled Linker-Immunoconjugates in Nude Mice and Dogs," J. Nucl. Med. 34:938-945, The Society of Nuclear Medicine, Inc. (1993)

EXAMINER

DATE CONSIDERED

*2/6/07*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
16/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 23, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


20	AR	11	Eistamäki, R., et al., "Serum CD44 in Malignant Lymphoma: An Association With Treatment Response," <i>Blood</i> 84:238-243, W.B. Saunders Company (1994)
20	AS	11	Eistamäki, R., et al., "CD44v6 Expression in Non-Hodgkin's Lymphoma: an Association with Low Histological Grade and Poor Prognosis," <i>J. Pathol.</i> 176:259-267, John Wiley & Sons, Ltd. (July 1995)
20	AT	11	Salles, G., et al., "Alternatively Spliced CD44 Transcripts in Diffuse Large-Cell Lymphomas: Characterization and Comparison With Normal Activated B Cells and Epithelial Malignancies," <i>Blood</i> 82:3539-3547, W.B. Saunders Company (1993)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 23, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AP	12	Savage, P., et al., "A recombinant single chain antibody interleukin-2 fusion protein," Br. J. Cancer 67:304-310, Macmillan Press, Ltd. (1993)
	AS	12	Screaton, G.R., et al., "Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons," Proc. Natl. Acad. Sci. USA 89:12160-12164, National Academy Press (1992)
	AT	12	Screaton, G.R., et al., "The Identification of a New Alternative Exon with Highly Restricted Tissue Expression in Transcripts Encoding the Mouse Pgp-1 (CD44) Homing Receptor," J. Biol. Chem. 268:12235-12238, The American Society for Biochemistry and Molecular Biology, Inc. (1993)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

## U.S. PATENT DOCUMENTS

EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED  
AUG 15 2002  
TECH CENTER 1600/2533

## FOREIGN PATENT DOCUMENTS

EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

h	AF	11	Seaver, S., "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought," Genet. Eng. News 14:10,21, Mary Ann Liebert, Inc. (1994)
w	AE	11	Seiter, S., et al., "Prevention of Tumor Metastasis Formation by Anti-Variant CD44," J. Exp. Med. 177:443-455, The Rockefeller University Press (1993)
h	AT	11	Stamenkovic, I., et al., "A Lymphocyte Molecule Implicated in Lymph Node Homing Is a Member of the Cartilage Link Protein Family," Cell 56:1057-1062, Cell Press (1989)

EXAMINER	DATE CONSIDERED 2/2/04
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0652.1910001/EKS/PSCAPPLICATION NO.  
10/052,641APPLICANT  
HEIDER et al.FILING DATE  
January 23, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED  
AUG 15 2002  
TECH CENTER 1600/2800

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


LA	AR	14	Stauder, R., et al., "CD44 Variant Isoforms in Non-Hodgkin's Lymphoma: A New Independent Prognostic Factor," <i>Blood</i> 85:2885-2899, W.B. Saunders Company (May 1995)
MB	AS	14	Tanabe, K.K., et al., "Expression of CD44R1 adhesion molecule in colon carcinomas and metastases," <i>Lancet</i> 341:725-726, Williams & Wilkins (1993)
AT	AT	14	Terpe, H.-J., et al., "CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues," <i>Histochemistry</i> 101:79-89, Springer-Verlag (1994)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 11/C52,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL2						Yes XNo
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

29	AR	15	Thomas, G.D., et al., "Antibodies for tumour immunodetecting and methods for antibody radiolabelling," in <i>Antibodies. Volume II. A Practical Approach</i> , Volume II, Catty, D., ed., IRL Press, Oxford, UK, pp. 223-244 (1989)
11	AS	15	Tölg, C., et al., "Splicing choice from ten variant exons establishes CD44 variability," <i>Nucl. Acids Res.</i> 21:1225-1229, Oxford University Press (1993)
20	AT	15	Vriesendorp, H.M. et al., "Review of Five Consecutive Studies of Radiolabeled Immunoglobulin Therapy in Hodgkin's Disease," <i>Cancer Res. (Suppl.)</i> 55:5888s-5892s, American Association for Cancer Research (December 1995)

EXAMINER 	DATE CONSIDERED 2/2/04
---	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642




## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	16	Dialog File 351, Accession No. 91-340908/199147, Derwent WPI English language abstract for EP 0 531 300 B1 (Document AL1)
	AS	16	Dialog File 351, Accession No. 93-136002/199317, Derwent WPI English language abstract for EP 0 538 754 A2 (Document AM1)
	AT	16	Dialog File 351, Accession No. 95-052230/199507, Derwent WPI English language abstract for WO 95/00851 (Document AP1)

EXAMINER 	DATE CONSIDERED 2/2/04
---	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.